New hope for kidney disease: drug targets genetic root cause
Disease control
Recruiting now
This study tests an experimental drug called MZE829 in 56 adults with chronic kidney disease caused by a specific genetic risk (APOL1). The goal is to see if the drug can reduce protein leakage into urine (a sign of kidney damage) and is safe. Participants must have the high-risk…
Phase: PHASE2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated May 17, 2026 15:00 UTC